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Abstract: Identification and quantification of functional cytochromes 
P450 (CYP450s) in biological samples is proving important for 
robust analyses of drug efficacy and metabolic disposition. In this 
paper, a novel CYP450 activity-based probe has been rationally 
designed and synthesised, demonstrating selective binding of 
CYP450 isoforms. The dependency of probe binding upon the 
presence of NADPH is permissive of selective detection of 
functionally active CYP450, allowing detection and analysis of these 
enzymes using biochemical and proteomic methodologies and 
approaches. 
Cytochrome P450s (CYP450s) constitute a large family of 
haem-centred enzymes, with fundamental roles in the 
biotransformation of endogenous (steroid hormones, fatty 
acids, prostaglandins) and exogenous molecules (drugs, 
environmental chemicals, agrochemicals). As a direct result of 
their importance, particularly in xenobiotic and drug 
metabolism,[1] a great deal of research has been conducted 
into the roles, identification of their sequences and their 
catalytic mechanism.[2-4] Whilst a number of CYP450s, 
particularly human liver CYP450s and extra-hepatic CYP450s 
(i.e. CYP1A1, CYP1B1 and CYP2W1) have been the subject 
of intense investigation,[5-7] much is still to be learnt from 
these mixed-function oxidases. This reflects the difficulties 
associated with studying these enzymes as (i) they are 
encoded by large gene families and their functions cannot be 
predicted from their gene sequence, (ii) they are difficult to 
assay, isolate and purify, so classical biochemical methods are 
often ineffectual in identifying enzymes of interest, (iii) these 
proteins are membrane bound and often dependent on co-
enzymes and co-factors, making them difficult to express as a 
functional enzymes in cellular systems, and (iv) 
polymorphisms and epigenetic regulation alter their 
expression and functional activity. As a result, new 
approaches to identifying, evaluating and quantifying 
functionally active CYP450s are of the upmost importance. 
One such approach is activity-based protein profiling, which 
involves ‘tagging’ the functional protein with a selective small 
molecule affinity probe, through covalent attachment (Figure 
1, pathway B)[8-13] 
 
Figure 1: SDS-PAGE activity based protein profiling, directly 
with appropriately functionalised probes (pathway A) or 
orthogonally utilising ‘click chemistry’ (pathway B). 
 
Whilst CYP450 probes developed to date exhibit the ability to 
bind these enzymes and thus indicate potential utility, several 
failed to demonstrate reactivity as a consequence of steric 
demands of the probe, and the majority lack differential or 
selective affinity for functional CYP450.[14-18] As a result, 
there is a requirement for new activity-based probes to study 
and identify this enzyme class. Here in, we report the 
synthesis of a small group of rationally designed activity-
based probes, identifying benzofurans as suitable 
pharmacophores, for this purpose. In addition, evaluation of 
the probes efficiency and ability to selectively label CYP450s 
was achieved using well-established biochemical techniques, 
such as enzyme kinetics, immunoblotting, and proteomic mass 
spectrometry. 
 
Results and discussion 
The probe designs were inspired from the natural product 
furanocoumarin family, which are known irreversible 
inhibitors of cytochrome P450s.[14-17] Our rationale focused on 
the structural elements required for a probe to function 
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efficiently and most importantly, selectively against 
cytochrome P450s. Furanocoumarins inhibit cytochrome 
P450s following oxidation of the furan moiety to yield a 
reactive furan epoxide, which undergoes nucleophilic attack 
from a protein amino acid side chain to covalently bind the 
apoprotein. Therefore a rational disconnection approach 
identified two structural analogues 7 and 8, with both 
retaining the furan moiety and a position for functionalization 
with a reporter group, whilst 8 possesses an additional 
aromatic ring to aid for greater selectivity in the active site 
(Figure 2). A third probe 9 was designed from coumarin, a 
known substrate for cytochrome P450s,[19, 20] to understand 
the requirement of the lactone fragment present in 
furanocoumarins. Coumarin is hydroxylated in the 7-position 
so it was envisioned, by installing a chloromethyl group in the 
6-position, the hydroxylated product would undergo 
rearrangement in the active site producing an ortho-quinone 
methide 5 which would undergo attack from a protein amino 
acid side chain, covalently linking the probe and enzyme 
(Figure 2). 
 
 
 
Figure 2: Mechanism of furanocoumarin inhibition; structural analogue for probe synthesis 
 
 
Synthesis of the furan and benzofuran probes 11 and 14 was 
achieved in a linear sequence beginning with the addition of 
mono-protected cadaverine[21, 22] to the activated carboxylic 
acids 7 and 12. Use of the reactive acid chloride of 7 led to 
satisfactory but low yielding amide 10, presumably due to the 
instability of the acid chloride. Notwithstanding this, 
expedient synthesis of probes 11 and 14 is achieved through 
TFA deprotection of the amides 10 and 13 followed by 
acylation with biotin-NHS. Synthesis of probe 20 was 
undertaken with a divergent approach starting from 2-
hydroxybenzaldehyde. Following a literature procedure,[23] a 
hydroxymethyl group was introduced with formaldehyde and 
conc. HCl to produce diol 15, with subsequent cyclisation of 
the aldehyde and phenolic hydroxyl group with Meldrums 
acid provided the coumarin architecture 16. Following a 
literature procedure[24] biotin was activated as the mixed 
anhydride, instead of the HOBt ester, and extended with 
mono-protected cadaverine[21, 22] providing 18 in good yield. 
Finally, 16 and 18 were joined through activation of the 
carboxylic acid moiety, and concomitant conversion of the 
hydroxylmethyl group to chloride, with thionyl chloride and 
deprotection of 18 with TFA to produce 20 in good yield over 
3 steps (Scheme 1). 
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Scheme 1: Reagents: (a.) (i.) SOCl2, DMF (cat.); (ii.) N-Boc-1,5-diaminopentane, DIPEA in DCM; (b.) (i.) 10 or 13, TFA, DCM; 
(ii.) Biotin-NHS, Et3N, DMF (c.) Meldrums acid, Pyridine, DCM, ; (d.) (i.) 16, SOCl2, ; (ii.) 18, TFA, DCM; (iii.) 17 + 19, xs. Et3N 
 
Biological investigations 
The ability and potential of probes 11, 14 and 20 to bind and 
inactivate CYP450 was evaluated using the Vivid assay,[25] for 
two recombinant enzymes; CYP3A4 a central component of 
many biotransformation processes known to be inhibited by 
furanocoumarins, and CYP1A2 that has an unknown 
endogenous substrate but broad exogenous substrate scope. [14, 
26] Initially, varying concentrations of methanol (11 and 14) 
and DMSO (20) solvent controls were assessed in the assay to 
determine if they had any deleterious effects. Unsurprisingly, 
DMSO was observed to be very toxic to the CYP3A4 assay, 
resulting in 50 % inhibition at 0.5 % DMSO which prevented 
the measurement of 20, which was only soluble in DMSO.[27, 
28] The CYP3A4 assay was also sensitive to methanol, but to a 
lesser extent and could be used up to concentrations of 10% in 
combination with water to dilute 11 and 14.[29] The CYP1A2 
assay, by contrast, was tolerant of DMSO to 2% as well as 
methanol to 10%. Consequently, dilutions of 11 and 14 in 4-
10% methanol/water for both CYP450s and dilutions of 20 in 
4% methanol/2% DMSO for CYP1A2 enabled determination 
of IC50 values for these enzymes.
[29] Probes 11, 14 and 20 
exhibited no significant inhibition of CYP1A2 activity at 
concentrations up to 2 mM, whereas 11 and 14 obtained inhibition 
of 230 and 90 M respectively against CYP3A4 (Error! 
Reference source not found.). In addition, the Kinact and the 
Ki were determined for 14, to be 0.042 (min
-1) and 0.5 mM 
respectively (Figure 3). 
 
Probe 
CYP3A4 inhibition  CYP1A2 inhibition  
(IC50; µM ±S.D.) (IC50; µM ±S.D.) 
11 230 ± 141 >2000 
14 90±7 >2000 
20 ND >2000 
Table 1: IC50 values for cytochrome P450 3A4 (n = 2 
measurements) and 1A2 (n = 3 measurements), ND – not 
determined 
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Figure 3. Kinact measurement of 14 for CYP3A4 
 
Having established that 11 and 14 are capable of inhibiting 
CYP3A4, their ability to act as a probe and identify the 
enzyme-probe complex was assessed. As 11 and 14 possess a 
biotin moiety, well-established streptavidin identification was 
utilised. Firstly, incubation of 11 and 14 with bactosomes, 
followed by streptavidin blotting revealed that both 11 and 14 
are activated by CYP3A4 and appear to covalently label the 
proteome, however multiple bands were detected with both 
probes.[29] These extra bands maybe the result of several 
factors, such as CYP3A4 aggregates and degradation products 
resulting from over expression of the gene in E.coli, or 
binding to E.coli proteins. The greater degree to which 11 
labels the proteome suggests it maybe released from the active 
site as the long lived ene-dial intermediate, formed from 
rearrangement of the furan epoxide (cf. 2), whilst 14 is a 
benzofuran which possesses an aromatic ring, increasing its 
binding affinity to the active site whilst also producing a more 
reactive benzofuran dioxetane, making labelling of the 
CYP450 more competitive. [30-33][34] 
 
As a result, subsequent studies were conducted with 14 as 
fewer off-target binding events were observed. Firstly, 
incubation of 14 with baculosomes, followed by desalting of 
the sample to remove free probe before binding to streptavidin 
magnetic beads and SDS PAGE analysis of the bound proteins 
was performed (Figure 4A). Pleasingly, 14 revealed a 
distinguishable strong band at ~55 kDa on staining with 
Coomassie-Blue, however additional bands were still 
detected. Subsequently, 14 was treated under the same 
conditions as before except were visualised by Western 
blotting with horseradish peroxidase-conjugated Streptavidin 
and ECLplus detection (Figure 4B). Satisfyingly, 14 produced 
a band at 55 kDa, indicative of binding and enrichment of 
CYP3A4. 
 
Having demonstrated that 14 was capable of identifying a 
band at approximately 55 kDa and with low off-target 
binding, attention turned to identifying the attached protein. 
Excision, digestion and analysis of the 55 kDa band from the 
Coomassie Blue stained gel  
 
 
 
Figure 4: A. Coomassie Blue-stained SDS polyacrylamide gel of 
CYP3A4 complexed with 14 and recovered from streptavidin 
magnetic beads. BS = baculosome CYP3A4 starting material; B. 
Streptavidin blot of 14, with no probe control incubated with 
CYP3A4 baculosomes. 
by mass spectrometry identified the protein to be CYP3A4 by 
peptide mass fingerprinting (Mascot score = 110, with 26 
matched peptides, MS threshold >56 was indicative of 
extensive homology) and MS/MS analysis of MH+ = 
1812.039 (score = 89, MS/MS threshold >30 was indicative of 
extensive homology), 1457.944 (score = 47) and 1960.278 
(score = 69).  
 
Satisfied with these results, attention turned to the selectivity 
of 14 against an array of bactosome-expressing CYP450s 
using streptavidin blotting. Probe 14 formed clear NADPH–
dependent complexes with CYP1B1, CYP2B6 and CYP3A4, 
and to a lesser extent CYP2C9. The promiscuity of CYP450s 
is not unexpected, as they have been implicated in the 
metabolism of a variety of xenobiotic compounds in human 
liver.[35-37] The level of selectivity displayed by 14 in binding 
to CYP450s in an NADPH-dependant manner with little to no 
binding observed in its absence is exemplary (Figure 5A). 
Using CYP3A4 as an example, the time- and NADPH-
dependent binding of 14 was shown to occur within 1 minute 
(Figure 5B).  
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Figure 5. A. Streptavidin blot of probe 14 incubated with 
bactosomes expressing a specific CYP450 isoform in the presence 
or absence of NADPH. B. Time course of 14 reaction with 
CYP3A4 
 
In conclusion, a small group of rationally designed probes 
have been synthesised, with a benzofuran probe 14 
demonstrating respectable inhibitory activity against CYP3A4 
(IC50 = 90 M). In addition, 14 was able to identify CYP3A4 
utilising well-established biochemical techniques, 
immunoblotting and mass spectrometry. There have been a 
number of studies to explore the binding of xenobiotics or 
activity based probes to cytochrome P450s, founded on 
coumarin and furan scaffolds. Furan is an established toxicant 
in liver and a screen of recombinant CYPs identified that 
CYP2E1 and CYP2D6 are enzymes responsible for its 
metabolism, with limited activity from CYP3A4.[38] There 
was inhibition of CYP3A4 activity in the Vivid assay by 
probe 11 (furan derivative) which may be due to bioactivation 
of the furan moiety resulting in the production of cis-2-
butene-1,4-dial which in turn reacts with lysine side chains 
and N-termini of proteins.[30] Coumarin and benzofuran 
derivatives (related to naturally occurring compounds in 
grapefruit juice) were synthesised and analysed for CYP3A4 
inhibition with the latter found to be the most potent.[39] Our 
benzofuran 14, exhibited the most effective NADPH-
dependent binding to CYP3A4 compared to other CYPs tested 
and consequently shows great promise for further 
investigation. Given the limited functionalization of 14, the 
level of selectivity demonstrated in binding CYP450s in an 
NADPH-manner was exemplary. In this respect, it is pertinent 
to note that a number of early CYP450 probes demonstrate 
similar selectivity for a range of CYP450s.[18] Work is 
currently in progress to further optimise the selectivity of 14 
and extend the library of probes to new CYP450s.  
Experimental Section 
All air and/or moisture sensitive reactions were carried out 
under an argon atmosphere. Solvents were purified and dried 
following established protocols. Petrol refers to petroleum 
spirit boiling in the 40-60 °C range. Ether refers to diethyl 
ether. All commercially available reagents were used as 
received unless otherwise stated. Flash column 
chromatography was performed according to the method of 
Still et al using 200-400 mesh silica gel.[40] Yields refer to 
isolated yields of products of greater than 95 % purity as 
determined by 1H + 13C NMR spectroscopy. Melting points 
were determined using Gallenkamp melting point apparatus 
and are uncorrected. Infrared spectra were recorded using a 
Diamond ATR (attenuated total reflection) accessory (Golden 
Gate) on a Perkin-Elmer FT-IR 1600 spectrometer. Unless 
otherwise stated 1H NMR spectra were recorded in CDCl3 on 
Varian Mercury-200, Varian VXR-400, Bruker Avance-400, 
Varian Inova-500, Varian VNMRS-700, and are reported as 
follows; chemical shift  (ppm) (number of protons, 
multiplicity, coupling constant J (Hz), assignment). Residual 
protic solvent CHCl3 (H = 7.26) was used as the internal 
reference. 13C NMR spectra were recorded at 63 MHz or 
126MHz, using the central resonance of CDCl3 (C = 
77.0 ppm) as the internal reference. All 13C spectra were 
proton decoupled. Assignment of spectra was carried out 
using DEPT, COSY, HSQC, HMBC and NOESY 
experiments. High resolution accurate mass measurement was 
performed on a LTQ FT mass spectrometer (ThermoFinnigan 
Corporation) using flow-injection electrospray ionisation.  
 
Standard procedure for the formation of 10 and 13 
The carboxylic acid 7 or 12 (1 equiv.) was treated with an excess 
of thionyl chloride and a drop of DMF. After stirring for the 
reported time and temperature, the solvent was removed in vacuo 
and the resultant material was dissolved and evaporated with DCM 
(3 x 10 ml) to ensure excess thionyl chloride removal. The 
resultant material was dissolved in DCM, treated with N-Boc-
cadaverine (1.2 equiv.) and DIPEA (4 equiv.) and stirred for the 
reported time and temperature. The reaction was then poured into 
sat. aq. NH4Cl (10 ml), dried with MgSO4, filtered and evaporated 
in vacuo. 
 
N-Boc-(5-aminopentyl)-3-furancarboxamide 10 
Following the standard procedure, 3-furoic acid 7 (100 mg, 0.9 
mmol) was transformed to a brown solid 10 (153 mg, 58 %); Rf 0.6 
(n-hexane/EtOAc 1:1); δH (400 MHz, CDCl3) 7.96 (1H, dd, J 1, 
Ar-H), 7.44 (1H, dd, J 2, Ar-H), 6.67 - 6.62 (1H, m, Ar-H), 5.99 
(1H, bs, NH), 4.62 (1H, bs, NHBoc), 3.44 - 3.39 (2H, q, J 8, CH2), 
3.15 (2H, m, CH2), 1.67 – 1.46 (6H, m, CH2), 1.45 (9H, s, NHBoc); 
δC (101 MHz, CDCl3) 162.7 (C=O), 156.2 (C=O), 144.7 (Ar-C), 
143.7 (Ar-C), 122.6 (ipso-Ar-C), 108.3 (Ar-C), 39.3 (CH2), 29.8 
(CH2), 29.2 (CH2), 28.4 (Boc), 23.9 (CH2); m/z (ES
+) 615.2 
(2M+Na+), 319.6 (MNa+), 297.2 (MH+) 
 
tert-Butyl 5-(benzofuran-5-carboxamido)pentylcarbamate 
13 
Following the standard procedure, benzofuran-5-carboxylic 
acid 12 (100 mg, 0.62 mmol) was transformed to a cream 
solid 13 (73 mg, 34 %); Rf 0.8 (n-hexane/EtOAc 1:1); max 
(ATR) 3372 (NH), 3328 (NH), 2932, 2870, 1685 (C=O), 1628 
(C=O), 1522, 1473, 1365, 1164, 1136, 1115, 1044, 1023, 
1012, 949, 908, 883, 847, 821 cm-1; H (700 MHz, CDCl3) 
8.06 (1H, d, J 2, Ar-H), 7.72 (1H, dd, J 9, 2, Ar-H), 7.68 (1H, 
d, J 2, Ar-H), 7.52 (1H, d, J 9, Ar-H), 6.82 (1H, dd, J 2, 1, Ar-
H), 6.24 (1H, bs, NH), 4.57 (1H, bs, NH), 3.49 (2H, q, J 6, 
CH2), 3.15 – 3.12 (2H, m, CH2), 1.69 – 1.64 (2H, m, CH2), 
1.58 – 1.51 (4H, m, CH2), 1.45 – 1.41 (9H, s, NHBoc); C 
(700 MHz, CDCl3) 167.0 (C=O), 156.5 (ipso-Ar-C), 156.1 
(ipso-Ar-C), 146.2 (Ar-C), 130.0 (ipso-Ar-C), 127.5 (ipso-Ar-
C), 123.3 (Ar-C), 120.6 (Ar-C), 111.4 (Ar-C), 107.0 (Ar-C), 
40.2 (CH2), 40.0 (CH2), 29.8 (CH2), 29.3(CH2), 28.4 (Boc), 
24.0 (CH2); m/z (ES
+) 369 (MNa+), 244 (M-Boc+); HRMS 
(ES+) Found MNa+, 369.1803 (C19H26N2O4Na requires 
369.1790). 
 
Standard procedure formation of 11 and 14 
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The N-Boc protected furancarboxamide 10 or 13 (0.2 – 0.4 mmol) 
was dissolved in DCM (5 ml) and treated with an excess of TFA 
(ca. 1 ml). After stirring for the reported time and temperature, the 
solvent was removed in vacuo and the resultant material was 
dissolved and evaporated with DCM (3 x 10 ml) to ensure excess 
TFA removal. The resultant material was then dissolved in DMF, 
treated with Biotin-NHS (1.1 equiv.) and Et3N (2.1 equiv.) and 
stirred for 4 hours. The solvent was then removed in vacuo and the 
resultant material flash chromatographed (DCM/methanol). 
Subsequent trituration with DCM (5 ml) produced the desired 
product.  
 
N-[5-(furan-3-ylformamido)pentyl]-5-{2-oxo-hexahydro-1H-
thieno[3,4-d]imidazolidin-4-yl}pentanamide 11 
Following the standard procedure, N-Boc protected 
furancarboxamide 10 (100 mg, 0.4 mmol) was transformed to a 
yellow solid 11 (113 mg, 79 %); Rf 0.3 (DCM/MeOH 9:1); δH (400 
MHz, CD3OD) 8.06 (1H, dd, J 1, Ar-H), 7.58 (1H, dd, J 2, Ar-H), 
6.81 (1H, dd, J 2, 1, Ar-H), 4.53 (1H, ddd, J 8, 5, 1, CHH), 4.32 
(1H, dd, J 8, 4, (CHH), 3.26 - 3.18 (4H, m, CH2), 2.72 (2H, m, 
CH2), 2.21 (2H, t, J 7, CH2), 1.82 – 1.39 (12H, m, CH2); m/z (ES
+) 
445 (MNa+), 424 (MH+) 
 
N-(5-(5-((3aS,4S,6aR)-2-Oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamido)pentyl)benzofuran-5-
carboxamide 14 
Following the standard procedure, tert-Butyl 5-(benzofuran-5-
carboxamido)pentylcarbamate 13 (100 mg, 0.29 mmol) was 
transformed to a white gummy solid 14 (100 mg, 73 %); Rf 
0.3 (DCM/MeOH 9:1); max (ATR) 3584 – 3072, 2940, 2868, 
1697 (C=O), 1676 (C=O), 1635 (C=O), 1524, 1461, 1316, 
1262, 1179, 1104, 1025, 826 cm-1; H (700 MHz, CD3OD) 
8.11 (1H, dd, J 2, 1, Ar-H), 7.84 (1H, d, J 2, Ar-H), 7.78 (1H, 
dd, J 9, 2, Ar-H), 7.56 (1H, dt, J 9, 1, Ar-H), 6.93 (1H, dd, J 
2, 1, Ar-H), 4.47 (1H, ddd, J 8, 5, 1 CH), 4.27 (1H, dd, J 8, 5, 
CH), 3.42 – 3.39 (3H, t, J 8, CH2), 3.21 – 3.15 (4H, m, CH2), 
2.90 (1H, dd, J 13, 5, CH2), 2.68 (1H, d, J 13, CH2), 2.17 (2H, 
m, CH2), 1.70 – 1.55 (4H, m, CH2), 1.45 – 1.38 (4H, m, CH2); 
C (700 MHz, CD3OD) 176.1 (C=O), 170.5 (C=O), 166.1 
(C=O), 158.0 (ipso-Ar-C), 147.9 (Ar-C), 130.9 (Ar-C), 128.9 
(ipso-Ar-C), 124.8 (Ar-C), 121.9 (ipso-Ar-C), 112.1 (Ar-C), 
108.1 (Ar-C), 63.4 (CH), 61.6 (CH), 56.9 (CH2), 41.05, 41.0, 
40.9, 40.2, 36.8, 30.11, 30.07, 29.7, 29.4, 26.9, 25.3; m/z 
(ES+) 967 (2M+Na+), 495 (MNa+), 473 (MH+); HRMS (ES+) 
Found MNa+, 495.2025 (C24H32N4O4SNa requires 495.2042). 
 
2-Hydroxy-5-(hydroxymethyl)benzaldehyde 15 
A mixture of salicylaldehyde (9 ml, 84.5 mmol), formaldehyde (17 
ml, 37 % aq., 200 mmol) and 42 ml of concentrated HCl was 
heated to 80 C for 20 min. After cooling, the supernatent was 
removed by settling of the phases and the residual pink crystalline 
mass was taken up in 200 ml of H2O. The suspension was refluxed 
for 30 min and then the supernatent was separated out after cooling. 
This step was repeated and the supernatants combined and placed 
at 4 C to bring about crystallisation. Filtration of the solid material 
and washing with H2O afforded the title compound as a white solid 
(1.7 g, 13 %); m.p. 105 - 107 C; max (ATR) 3418 – 3120 (broad – 
OH), 2876, 1651, 1578, 1481, 1454, 1376, 1358, 1307, 1274, 1187, 
1145, 1017, 902, 839 cm-1; H (500 MHz, CDCl3) 11.0 (1H s Ar-
CHO), 9.92 (1H, s, Ar-OH), 7.59 (1H, d, J 2, Ar-H), 7.54 (1H, dd, 
J 9, 2, Ar-H), 7.0 (1H, d, J 9, Ar-H), 4.70 (2H, s, Ar-CH2); C (500 
MHz, CDCl3) 196.5 (C=O), 161.1 (ipso-Ar-C), 136.0 (Ar-C), 
132.9 (Ar-C), 132.1 (Ar-C), 120.3 (ipso-Ar-C), 117.8 (Ar-C), 64.2 
(CH2); m/z (ES
-) 151 (MH-); HRMS (ES-) Found MH-, 151.0391 
(C8H7O3 requires 151.0395). 
 
6-(Hydroxymethyl)-2-oxo-2H-chromene-3-carboxylic acid 16 
2-Hydroxy-5-(hydroxymethyl)benzaldehyde (1.2 g, 7.9 mmol) was 
dissolved in DCM and treated with Meldrums acid (1.4 g, 9.5 
mmol) and pyridine (1.3 ml, 15.8 mmol). The solution was 
refluxed for 2 h, then after cooling the precipitate was collected by 
filtration and washed with DCM to afford the title compound as a 
pale yellow solid (1.2 g, 70 %); H (400 MHz, DMSO) 8.43 (1H, s, 
Ar-H), 7.73 (1H, s, Ar-H), 7.58 (1H, dd, J 9, 2, Ar-H), 7.34 (1H, s, 
Ar-H), 4.55 (2H, s, Ar-CH2); m/z (ES
+) 243 (MNa+), 221 (MH+); 
all data agree with those reported in the literature.[23] 
 
6-(Chloromethyl)-2-oxo-N-(5-(5-((3aS,4S,6aR)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamido)pentyl)-2H-chromene-3-carboxamide 20 
6-(Hydroxymethyl)-2-oxo-2H-chromene-3-carboxylic acid 16 (50 
mg, 023 mmol) was dissolved in thionyl chloride (4 ml) and 
refluxed for 2 h. At the same time, tert-butyl 5-(5-((3aS,4S,6aR)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamido)pentylcarbamate[24] 18 (97 mg, 0.23 mmol) was 
dissolved in DCM (2 ml) and treated with TFA (2 ml). Evaporation 
of the two reactions to remove the thionyl chloride and TFA was 
followed by dissolution of the two reactions in DCM (2 ml). The 
crude 6-(chloromethyl)-2-oxo-2H-chromene-3-carbonyl chloride 
17 was then added via cannulla to a mixture of crude N-(5-
aminopentyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamide 19 and Et3N (95 l, 0.7 mmol) at 
room temperature. The reaction was stirred for 2 h and then 
evaporated. Flash chromatography (DCM, DCM/MeOH [99:1], 
[98:2], [95:5], [9:1]) followed by trituration with MeOH afforded 
the title compound as a white gummy solid (55 mg, 44 %); Rf 0.3 
(DCM/MeOH 9:1); max (ATR) 3512 – 3150, 2928, 2854, 1697 
(C=O), 1653 (C=O), 1614 (C=O), 1573, 1536, 1419, 1246, 1168, 
1021, 827 cm-1; H (500 MHz, DMSO) 8.80 (1H, s, Ar-H), 8.67 
(1H, t, J 6, NH), 8.02 (1H, d, J 2, Ar-H), 7.80 (1H, dd, J 9, 2, Ar-
H), 7.52 (1H, d, J 9, Ar-H), 6.42 (1H, s, NH), 6.35 (1H, s, NH), 
4.84 (2H, s, Ar-CH2), 4.29 (1H, m, CH), 4.15 (1H, m, CH), 3.09 – 
3.00 (4H, m, CH2), 2.80 (2H, dd, J 12, 5, CH2), 2.64 (2H, m, CH2), 
2.02 (2H, t, J 6, CH2), 1.62 – 1.23 (6H, m, CH2), 1.15 (2H, t, J 6, 
CH2); C (500 MHz, DMSO) 172.6 (C=O), 163.4 (ipso-Ar-C), 
161.6 (C=O), 161.0 (C=O), 154.2 (C=O), 147.5 (Ar-C), 135.39 
(ipso-Ar-C), 135.20 (Ar-C), 130.9 (Ar-C), 120.4 (ipso-Ar-C), 
119.2 (ipso-Ar-C), 117.4 (Ar-C), 61.7, 59.9, 56.1, 46.4, 45.7, 38.9, 
35.9, 29.5, 29.4, 28.9, 28.7, 26.0, 24.5, 9.3; m/z (ES+) 549 
([35Cl]MH+); HRMS (ES+) Found [35Cl]MH+, 549.1928 
(C26H34
35ClN4O5S requires 549.1938). 
 
Baculosome CYPs.  
Baculosome CYP1A2 and CYP3A4 were purchased from 
ThermoFisherScientific, were used for the Vivid assays and 
streptavidin affinity enrichment. 
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Cytochrome P450 Fluorescent Assays 
The Vivid® CYP3A4 assay (Life Technologies, Carlsbad, 
CA) was run according to the manufacturer’s instructions. A 
master pre-mix was prepared comprising, 4500 µl of 100 mM 
potassium phosphate buffer, pH 8.0, 100 μl of Regeneration 
System (333 mM glucose-6-phosphate and 30 U/ml glucose-
6-phosphate dehydrogenase in 100 mM potassium phosphate 
buffer, pH 8.0) and 400 μl of CYP3A4 BACULOSOMES® 
(microsomes from baculovirus-infected cells co-expressing 
human CYP3A4, NADPH-cytochrome P450 reductase and 
human cytochrome b5). An aliquot of master pre-mix  (50 µl) 
was pre-incubated with 40 μl of either 10% methanol (control) 
or serial dilutions of 1 mM solutions of probes 11 or 14 in 
10% methanol, in a 96-well plate (Nunc™, ThermoFisher 
Scientific) for 10 minutes at room temperature. The reaction 
was initiated with the addition of 10 µl of the substrate 
solution (920 µl of 100 mM PBS, pH 8.0, 30 µl NADP+ and 
50 µl 3A4 substrate, 7-benzyloxy-methyloxy-3-
cyanocoumarin). Final concentrations were as follows: 
CYP3A4 – 40nM, BOMCC – 10M, NADP+ - 30M, G6P – 
3.33mM, and G6PD – 0.3U/ml. The relative fluorescence 
units (RFU) readings were then taken continuously every 
minute for 30 minutes using the Fluoroskan Ascent FL 
Microplate Fluorometer and Luminometer (Thermo Fisher 
Scientific, UK) and Ascent software version 2.6 (Thermo Lab 
systems, UK), with 390 nm and 460 nm, excitation and 
emission wavelengths respectively. 
The assay for CYP1A2 was analogous to that described for 
CYP3A4. A master pre-mix was prepared comprising, 2800 
µL of 10 mM PBS (pH 7.4) 100 μL of regeneration system 
and 100 μL of CYP1A2 BACULOSOMES® (microsomes 
from baculovirus-infected cells co-expressing human 
CYP1A2, NADPH-cytochrome P450 reductase and human 
cytochrome b5). An aliquot of master pre-mix (30 µL) was 
pre-incubated with 40 µl of each dilution of a probe for 10 
minutes at 37°C with in the Fluoroskan Ascent FL Microplate 
Fluorometer and Luminometer. The reaction was initiated 
with addition of 30 µL of the CYP1A2 substrate solution 
(2940 µL of 10mM, PBS pH 7.4, 30 µL NADP+ and 30 µL 7-
ethoxymethoxy-3-cyanocoumarin) which was also pre-
incubated at 37°C. Final concentrations were as follows: 
CYP1A2 – 10nM, EOMCC – 2M, NADP+ - 10M, G6P – 
3.33mM, and G6PD – 0.3U/ml. The fluorescent readings were 
taken in the similar way as described above. The effect of 
each probe was calculated by comparing relative fluorescent 
unit (RFU) with the control assay containing 40 µL of PBS 
instead of the probe. To investigate IC50 values for both 
assays, non-linear regression analysis was done using 
GraphPad Prism 6 software. 
Probe-bactosome expressed CYP reactions 
Human CYP1B1, 2B6, 2C19, 2D6, 2E1, 3A4 and 4A11, along 
with control bactosomes expressed in Escherichia coli, were 
purchased from Cypex (Dundee, UK) and used to screen 
streptavidin blots for specificity, reaction time and 
concentration (Figure 5). Each was co-expressed with human 
cytochrome P450 reductase, and CYP3A4 and 4A11 also 
contained cytochrome b5. The expression levels (nmoles or 
μg of CYP per mg of total protein) for each CYP were 
different for each product. Therefore, each CYP (1 μg, 
equivalent to 16 to 18 pmoles of CYP, Figure 5) was diluted 
with PBS to a concentration of 0.05 μg/μl. Control 
bactosomes were diluted in PBS to give a 4.25 μg/μl protein 
solution, which was equivalent to the average protein 
concentration for the CYP bactosomes used. Each experiment 
was performed in duplicate to confirm reproducibility. For 
CYP profiling, each reaction, NADPH (1 mM, Sigma, Poole, 
UK) or PBS for NADPH-negative controls, was added to a 
0.05μg/μl of PBS solution of one of the CYPs or control 
bactosomes.  
 
CYP 1B1, 2B6, 2C9, 2D6, 2E1, 3A4 and 4A11 were obtained 
from CYPEX as membrane suspensions containing 1nmol 
P450/ml at 580, 88, 306, 282, 370, 327 and 147 pmol/mg 
protein. 
 
Probe 14  (5mM in PBS, 20 % methanol) was added to each 
reaction mixture (equivalent to final concentrations of 0.5 
mM), incubated at room temperature for 60 minutes before 
the reactions were stopped by transfer to reducing SDS 
loading buffer. For a time course experiment, NADPH (1 
mM, Sigma, Poole, UK) or PBS for a NADPH-negative 
control was added to a 0.05μg/μl of PBS solution of CYP3A4. 
An aliquot was removed from each reaction (representing 
T=0) and transferred to 4 μl of reducing SDS loading buffer. 
Probe 14 (5mM in PBS, 20 % methanol) was added to each 
reaction and aliquots removed at 1, 10 and 60 minutes. Each 
aliquot was transferred to reducing SDS loading buffer to stop 
the reaction. 
 
SDS PAGE/Streptavidin-HRP blotting  
Samples (16 – 18 pmol CYP) were applied to 10 % SDS-
PAGE gels at 80 V (Bio-Rad Laboratories, Hemel 
Hempstead, UK) for 15 minutes then at 150 V for 60 minutes. 
Following this, the gel was transferred to a nitrocellulose 
membrane (GE Healthcare, Amersham, UK) at 58 mA (Bio-
Rad Laboratories, UK) for two hours. After transferring, 
membranes were blocked by 5 % milk powder at 4 oC 
overnight followed by a further 30 minutes at room 
temperature. After three washes with TBS-Tween-20 (0.05 %) 
for 15 minutes, the membranes were incubated with 
horseradish peroxidase-conjugated Streptavidin (Abcam, 
Cambridge, UK) at a dilution of 1:500 in 5 % blocking buffer 
for 1 hour at room temperature. Membranes were washed a 
further three times, each time incubated for 15 minutes at 
room temperature. ECL plus (GE Healthcare) was used for 
Streptavidin detection followed by exposure using imaging 
film (GE Healthcare). 
 
Affinity purification using immobilised probes and mass 
spectrometric analysis 
CYP3A4 baculosomes, equivalent to 5g of recombinant 
CYP3A4, were incubated with probe 14 or PBS for 15 
minutes at 37 oC. Each reaction mixture was desalted in NAP-
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5 size exclusion columns (GE Healthcare, UK), equilibrated 
with 10mM ammonium bicarbonate, to remove free probe. 
The protein-probe complex, was lyophilised, resuspended in 
PBS incubated with bovine serum albumin pre-coated 
streptavidin Dynabeads (Life Technologies, Paisley). After 
three PBS, three 1M NaCl phosphate buffer and three 10mM 
ammonium bicarbonate, 10 % acetonitrile washes, the beads 
were resuspended in SDS PAGE Laemmli buffer and 
incubated at 90 oC for 15 minutes. The proteins released from 
the beads by the buffer were separated by SDS PAGE and 
stained with Coomassie Blue R-250 (Thermo Fisher 
Scientific). Bands of interest were excised from the gel and 
subject to in-gel digestion.[41] The resulting peptides were 
desalted in C18 ZipTips (Millipore) and analysed by MALDI 
MS in reflectron, positive ion mode (Ultraflex II, Bruker 
Daltonik, Bremen) for peptide mass fingerprinting and 
MS/MS for selected peptide fragmentation. The resulting 
spectra were searched using Mascot version 2.4 (Matrix 
Science, UK) against SwissProt version 2015_06 (Homo 
sapiens, 20207 sequences) to identify the proteins. 
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Identification of functional cytochrome P450 (CYP450) enzymes in primary tissues is important for the robust analysis of drug efficacy 
and metabolism. In this paper we describe the synthesis of a novel CYP450 activity-based probe, which demonstrates selective 
binding of human recombinant CYP450 isoforms. 
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